The organization is slowing down cloud adoption due to complexity and compliance concerns, instead increasing reliance on on-prem infrastructure in 2024. Separate tools are used by different teams for security. There’s an investment in cloud skill development for employees, but plans for expanding the multi-cloud environment are also underway.
Novo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros Drug
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused
